Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The stability and biological behavior of an in vitro system of doxorubicin (DXR) entrapped in NK911, polymer micelles, was examined and compared with those of DXR entrapped in Doxil, polyethylene‐glycol‐conjugated liposomes. The fluorescence of DXR inside micelles or liposomes in an aqueous solution is known to be strongly quenched by the outer shells of the micellar or liposomal formation. Thus, by measuring the fluorescence intensity of DXR released from NK911 or Doxil, we could determine the stability of the micellar or liposomal DXR formation. Furthermore, NK911 was found to be less stable than Doxil in saline solution. In drug distribution experiments using an in vitro solid tumor model, when spheroids formed from two human colonic cancer lines, HT‐29 and WiDr, and a human stomach cancer line, MKN28, were exposed to NK911, DXR was distributed throughout the spheroids, including their center. On the other hand, when the spheroids were exposed to Doxil, DXR was distributed only to the surface of the spheroids. It has been suggested that Doxil can deliver DXR to a solid tumor more efficiently than NK911 via the EPR (enhanced permeability and retention) effect, because Doxil may be more stable in plasma than NK911. On the other hand, DXR packed in NK911 may be distributed by diffusion to cancer cells distant from the tumor vessel, because NK911 can leak out of the tumor vessel and may be able to release free DXR more easily than Doxil. It has been suggested that drug carrier systems such as liposomes and micelles should be selected appropriately bearing in mind the characteristics of the tumor vasculature and the tumor interstitium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yokoyama, M. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00115-6 · Cited by 308
Watersoluble polymers in medicine
Bader, H., Ringsdorf, H., & Schmidt, B. (1984) · Die Angewandte Makromolekulare Chemie · doi:10.1002/apmc.1984.051230121 · Cited by 291
Cited by
Nishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Bae, Y., Nishiyama, N., Fukushima, S., Koyama, H., Yasuhiro, M., & Kataoka, K. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0498166 · Cited by 742
Bae, Y., & Kataoka, K. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.016 · Cited by 669
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
“Thus, NK911, which only contains DXR monomers, is less stable in aqueous media than the original form of micellar DXR (Nakanishi et al, 2001; Tsukioka et al, 2002).”
BackgroundSelf-citation
Metadata
- Authors
- Tsukioka, Y., Matsumura, Y., Hamaguchi, T., Koike, H., Moriyasu, F., & Kakizoe, T.
- Venue
- Japanese Journal of Cancer Research
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 93
- Issue
- 10
- Pages
- 1145-1153
- ISSN
- 0910-5050 (ISSN-L)
- OpenAlex
- W2034387263
- Cited by
- 114
- References
- 2
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil). https://app.cochat.ai/papers/10.1111/j.1349-7006.2002.tb01217.x
- The paper
- Tsukioka, Y., Matsumura, Y., Hamaguchi, T., Koike, H., Moriyasu, F., & Kakizoe, T. (2002). Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil). Japanese Journal of Cancer Research. https://doi.org/10.1111/j.1349-7006.2002.tb01217.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.